Identification of novel oncogenes/oncomirs located at 13q involved in the progression of colorectal adenoma to carcinoma
10 / 2010 - onbekend
Colorectal cancer (CRC) is the second leading cause of cancer death in the western world with over 4200 deaths per year in the Netherlands. Secondary prevention is the most realistic approach for reducing this high number of CRC deaths. At present, options for secondary prevention include immunological fecal occult blood testing (FIT) and endoscopic screening. FIT is easy and well tolerated, but has a low sensitivity and specificity. Therefore, a need exists to improve the sensitive and specific CRC stool based tests, by, for instance, incorporating molecular (DNA, RNA or protein) biomarkers. Understanding the molecular pathology of CRC is crucial to unravel candidate molecular biomarkers. Candidate diagnostic biomarkers have been and are being identified based on two complementary approaches, i.e. tumor profiling studies of large collections of clinically well-characterized tumor and stool samples, and functional analysis of the effects of candidate biomarkers on tumor biology. To this end it is investigated whether promoter methylation, DNA copy number status, miRNA profiling, and protein detection can be used as a molecular test in CRC population screening. Endoscopic screening has a ±90% sensitivity for detecting colorectal adenomas, but since only 5% of all adenomas ever progress to CRC, endoscopy has a low specificity in terms of CRC prevention. Moreover, colonoscopy is a burdensome procedure for screenees. Therefore, a need exists for more specific, non-invasive imaging of CRC. Molecular imaging by MRI is a promising, non-invasive technique to gain molecular information about colon tumors. To this end, we aim to identify imageable biomarkers for adenomas at high risk of progression and CRCs.